Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Multi-center, Open-label Proof of Concept Safety and Efficacy Study of FCR001 Cell-based Therapy in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis at Risk for Organ Failure

NCT05098145 is registered in ClinicalTrials.gov with Talaris Therapeutics Inc. as lead sponsor.

NCT NCT05098145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05098145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Multi-center, Open-label Proof of Concept Safety and Efficacy Study of FCR001 Cell-based Therapy in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis at Risk for Organ Failure
Lead sponsor
Talaris Therapeutics Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
November 24, 2021
Completion date
February 28, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis